Literature DB >> 2992777

Tumorigenicity and transcriptional modulation of c-myc and N-ras oncogenes in a human hepatoma cell line.

B E Huber, K L Dearfield, J R Williams, C A Heilman, S S Thorgeirsson.   

Abstract

Tumorigenicity and oncogene expression were examined in HepG2 derived cells, a human hepatoma cell line. HepG2 cells and a single cell clonal HepG2 line, HLD2-6, were equally tumorigenic when injected s.c. into athymic nude mice. Cyclophosphamide pretreatment of both cell lines (500 micrograms cyclophosphamide/ml/two cell cycles) had no effect on tumor incidence or latency (P greater than 0.05). Tumors were nonencapsulated, highly invasive adenocarcinomas and were positive for gamma-glutamyltranspeptidase activity and bile production. Plasma from tumor-bearing mice was positive for human alpha-fetoprotein and negative for hepatitis B virus surface antigen as measured by radioimmunoassay. Two cell lines reestablished into tissue culture from HLD2-6 derived tumors had unaltered cell cycle times. Detailed in vitro translation analysis of RNA isolated from HLD2-6 derived cells and tumors were extremely similar to the translation products of RNA isolated from a normal human liver sample except for a Mr 53,000 polypeptide with an apparent charge shift. c-myc specific transcripts, when compared to a normal human liver sample, were increased in all HLD2-6 cell lines and tumors derived from HLD2-6 cells. This increase in c-myc expression could not be explained by gene amplification or hepatitis B virus integration. N-ras specific transcripts were not elevated in HLD2-6 cells grown in tissue culture but there was a selective increase of the 5.5-kilobase N-ras transcript in HLD2-6 derived tumors grown in nude mice. This increased 5.5-kilobase transcript did not remain elevated if the tumors were reestablished into tissue culture, suggesting some interaction with the host animal. c-Ha-ras expression could not be detected in any HLD2-6 derived tumor or cell line.

Entities:  

Mesh:

Year:  1985        PMID: 2992777

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  6 in total

1.  A novel inverse relationship between metformin-triggered AMPK-SIRT1 signaling and p53 protein abundance in high glucose-exposed HepG2 cells.

Authors:  Lauren E Nelson; Rudy J Valentine; José M Cacicedo; Marie-Soleil Gauthier; Yasuo Ido; Neil B Ruderman
Journal:  Am J Physiol Cell Physiol       Date:  2012-02-29       Impact factor: 4.249

2.  Tumorigenicity of simian virus 40-hepatocyte cell lines: effect of in vitro and in vivo passage on expression of liver-specific genes and oncogenes.

Authors:  C D Woodworth; J W Kreider; L Mengel; T Miller; Y L Meng; H C Isom
Journal:  Mol Cell Biol       Date:  1988-10       Impact factor: 4.272

3.  Evaluation of the potent anti-hepatitis B virus agent (-) cis-5-fluoro-1-[2-(hydroxymethyl)-1,3-oxathiolan-5-yl]cytosine in a novel in vivo model.

Authors:  L D Condreay; R W Jansen; T F Powdrill; L C Johnson; D W Selleseth; M T Paff; S M Daluge; G R Painter; P A Furman; M N Ellis
Journal:  Antimicrob Agents Chemother       Date:  1994-03       Impact factor: 5.191

4.  Pathways for the mutagenesis of 1-nitropyrene and dinitropyrenes in the human hepatoma cell line HepG2.

Authors:  K J Silvers; E P Eddy; E C McCoy; H S Rosenkranz; P C Howard
Journal:  Environ Health Perspect       Date:  1994-10       Impact factor: 9.031

5.  Regulation of transforming growth factor is involved in the efficacy of combined 5-fluorouracil and interferon alpha-2b therapy of advanced hepatocellular carcinoma.

Authors:  Youhei Okada; Ting Wang; Kazuhiro Kasai; Kazuyuki Suzuki; Yasuhiro Takikawa
Journal:  Cell Death Discov       Date:  2018-03-12

6.  Hepatitis B virus DNA detection by in situ hybridization in human hepatocellular carcinoma.

Authors:  D H Lee; J D Lee
Journal:  Korean J Intern Med       Date:  1988-01       Impact factor: 2.884

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.